NeoGenomics, Inc. (NASDAQ:NEO) Position Lessened by US Bancorp DE

US Bancorp DE lowered its position in NeoGenomics, Inc. (NASDAQ:NEO) by 29.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,815 shares of the medical research company’s stock after selling 763 shares during the quarter. US Bancorp DE’s holdings in NeoGenomics were worth $27,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Arizona State Retirement System grew its stake in shares of NeoGenomics by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 35,739 shares of the medical research company’s stock valued at $496,000 after buying an additional 708 shares in the last quarter. Crossmark Global Holdings Inc. lifted its stake in NeoGenomics by 2.9% in the second quarter. Crossmark Global Holdings Inc. now owns 29,494 shares of the medical research company’s stock valued at $409,000 after acquiring an additional 842 shares during the last quarter. Blue Trust Inc. grew its position in NeoGenomics by 42.3% in the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after acquiring an additional 987 shares in the last quarter. Oppenheimer Asset Management Inc. increased its stake in shares of NeoGenomics by 3.3% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 32,505 shares of the medical research company’s stock worth $451,000 after purchasing an additional 1,030 shares during the last quarter. Finally, Louisiana State Employees Retirement System raised its holdings in shares of NeoGenomics by 1.9% during the 2nd quarter. Louisiana State Employees Retirement System now owns 64,300 shares of the medical research company’s stock valued at $892,000 after purchasing an additional 1,200 shares in the last quarter. 98.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on NEO. Benchmark reiterated a “buy” rating and issued a $18.00 price objective on shares of NeoGenomics in a report on Tuesday, September 24th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of NeoGenomics in a research report on Wednesday, November 6th. Finally, Stephens reissued an “overweight” rating and set a $19.00 price objective on shares of NeoGenomics in a report on Tuesday, July 30th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $20.25.

NeoGenomics Stock Down 0.2 %

NASDAQ NEO opened at $15.01 on Tuesday. NeoGenomics, Inc. has a twelve month low of $12.77 and a twelve month high of $21.22. The stock has a market cap of $1.93 billion, a PE ratio of -24.66 and a beta of 1.19. The firm has a 50-day simple moving average of $14.67 and a 200 day simple moving average of $14.82. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The business had revenue of $167.80 million during the quarter, compared to analyst estimates of $167.00 million. During the same period in the prior year, the company posted ($0.06) earnings per share. NeoGenomics’s revenue was up 10.5% on a year-over-year basis. On average, research analysts forecast that NeoGenomics, Inc. will post -0.17 EPS for the current year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.